Sector News

Categories

Borderless Insights

Image
How to impress the headhunter: Andrew Kris in conversation with Anthony Harling provide the clues.
Image
Now performing in the biotech big top: The Chief Medical Officer
Image
What can the Life Sciences sector and other industries learn from Amazon

Roche buys France’s Trophos in 470 million euro deal

January 16, 2015
Life sciences
Roche has hit the acquisition trail to buy France’s Trophos in a deal that could be worth 470 million euros.
 
Trophos, a privately-held biotech based in Marseille, France, has developed olesoxime, which is being developed for spinal muscular atrophy – a rare and debilitating genetic neuromuscular disease that is most commonly diagnosed in children. Results from a Phase II trial have shown a beneficial effect on the maintenance of neuromuscular function and a reduction in medical complications associated with the disease.
 
Under the terms of the agreement, Trophos’ shareholders will receive 120 million euros upfront and up to 350 million euros based on achievement of predetermined milestones.
 
Roche’s chief medical officer Sandra Horning said “we will build on the work done by Trophos and the French Muscular Dystrophy Association to advance the development of olesoxime and to bring it to people who live with this devastating condition as quickly as possible”. The compound has orphan drug status on both sides of the Atlantic.
 
The deal rounds off a busy week for Roche, which has paid over $1 billion to acquire a majority stake in molecular information company Foundation Medicine. The Swiss giant licensed an early-stage treatment for antibiotic resistance from Japan’s Meiji Seika Pharma and Fedora of Canada in a deal that could be worth $750 million.
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

September 17, 2022

Novo Nordisk partners with Microsoft for AI-driven drug discovery

Life sciences

Novo Nordisk has signed a new strategic partnership with Microsoft to expedite the discovery and development of drugs leveraging big data and artificial intelligence (AI). Under the deal, Microsoft’s computational services, Cloud and artificial intelligence (AI) will be merged with the drug discovery, development and data science expertise of Novo Nordisk.

Read more
September 17, 2022

Bayer’s hunt for a new CEO is on, suggesting Werner Baumann could be headed for an early exit: report

Life sciences

Following years of push-and-pull over the German conglomerate’s top post, Bayer has quietly started a hunt for Baumann’s successor, Bloomberg News reported Tuesday, citing people close to the matter. The new CEO search may portend an early departure for Baumann, whose contract with Bayer isn’t set to expire until April 2024.

Read more
September 17, 2022

Bluebird CFO resigns ahead of gene therapy launch

Life sciences

Bluebird bio on Monday said its chief strategy and financial officer, Jason Cole, will leave the company this fall, marking the second time in less than a year the cash-strapped gene therapy developer will replace its top financial executive.

Read more
More news